ArticleAmerican journal of hematology2017

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.